報價延遲最少15分鐘:2025/09/04 05:14 EDT
盤前時段
|
||||
|
-- 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
19.37
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.01/0.11
|
|
企業價值
1.03B
|
| 資產負債 |
|
每股賬面淨值
-1.00
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
90.40M
|
|
每股收益
1.57
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/09/04 05:14 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablationin forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales. |
